197 related articles for article (PubMed ID: 22643562)
21. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
[TBL] [Abstract][Full Text] [Related]
22. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
23. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
[TBL] [Abstract][Full Text] [Related]
26. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
Koukourakis MI; Tsoutsou PG; Abatzoglou I
Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
[TBL] [Abstract][Full Text] [Related]
27. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
29. The relationship between local dose and loss of function for irradiated lung.
Gopal R; Tucker SL; Komaki R; Liao Z; Forster KM; Stevens C; Kelly JF; Starkschall G
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):106-13. PubMed ID: 12694828
[TBL] [Abstract][Full Text] [Related]
30. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
31. Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery.
Manavis J; Ambatzoglou J; Sismanidou K; Koukourakis MI
Am J Clin Oncol; 2006 Oct; 29(5):479-83. PubMed ID: 17023783
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
33. Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Myerson R; Zobeiri I; Birnbaum E; Dietz D; Fleshman J; Kodner I; Picus J; Ratkin G
Semin Oncol; 2002 Dec; 29(6 Suppl 19):29-33. PubMed ID: 12577240
[TBL] [Abstract][Full Text] [Related]
34. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
35. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
36. Managing toxicities in pelvic malignancies.
Friedland J
J Support Oncol; 2004; 2(6 Suppl 3):19-23. PubMed ID: 15605921
[TBL] [Abstract][Full Text] [Related]
37. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
38. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
[TBL] [Abstract][Full Text] [Related]
39. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
40. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
Fleischer G; Dörr W
Strahlenther Onkol; 2006 Oct; 182(10):567-75. PubMed ID: 17013569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
